Velindre Library
@vcclibrary.bsky.social
Velindre University NHS Trust Library, the only cancer specialist library service in Wales. Supporting NHS and academic staff, students and health professionals.
Reposted by Velindre Library
Coming from mid-November 2025 for Cochrane reviews:
💥 A new AI disclosure section across all reviews
💥 Changes to all reviews types to reflect evolving methodological best practice & to align with recent changes to intervention reviews
💥 Changes to how rapid reviews are managed
💥 A new AI disclosure section across all reviews
💥 Changes to all reviews types to reflect evolving methodological best practice & to align with recent changes to intervention reviews
💥 Changes to how rapid reviews are managed
Clearer, more consistent Cochrane reviews are coming.
From mid-November, we’re updating reporting formats to make reviews easier to use, more accessible, and more impactful.
🔗 www.cochrane.org/about-us/new...
From mid-November, we’re updating reporting formats to make reviews easier to use, more accessible, and more impactful.
🔗 www.cochrane.org/about-us/new...
September 23, 2025 at 11:56 AM
Coming from mid-November 2025 for Cochrane reviews:
💥 A new AI disclosure section across all reviews
💥 Changes to all reviews types to reflect evolving methodological best practice & to align with recent changes to intervention reviews
💥 Changes to how rapid reviews are managed
💥 A new AI disclosure section across all reviews
💥 Changes to all reviews types to reflect evolving methodological best practice & to align with recent changes to intervention reviews
💥 Changes to how rapid reviews are managed
Reposted by Velindre Library
Alongside @campbellreviews.bsky.social, @jbiebhc.bsky.social, and @envevidence.bsky.social we have published a position statement on the responsible use of #AI in #EvidenceSynthesis.
This collaborative effort is an important step.
Find out more: www.cochrane.org/about-us/new...
This collaborative effort is an important step.
Find out more: www.cochrane.org/about-us/new...
November 11, 2025 at 2:31 PM
Alongside @campbellreviews.bsky.social, @jbiebhc.bsky.social, and @envevidence.bsky.social we have published a position statement on the responsible use of #AI in #EvidenceSynthesis.
This collaborative effort is an important step.
Find out more: www.cochrane.org/about-us/new...
This collaborative effort is an important step.
Find out more: www.cochrane.org/about-us/new...
Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review www.clinicaloncologyonline.net/article/S093... #Cancer @velindrecc.bsky.social
Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review
Oesophago-gastric cancers are the fifth most common in the UK. Most patients present
with advanced disease and are unsuitable for curative surgery, instead receiving palliative
treatment to improve pr...
www.clinicaloncologyonline.net
November 14, 2025 at 11:58 AM
Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review www.clinicaloncologyonline.net/article/S093... #Cancer @velindrecc.bsky.social
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology www.nature.com/articles/s41... #Cancer
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology - British Journal of Cancer
British Journal of Cancer - Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
www.nature.com
November 14, 2025 at 11:53 AM
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology www.nature.com/articles/s41... #Cancer
#ProstateCancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology jnccn.org/view/journal... #Cancer
jnccn.org
November 14, 2025 at 11:47 AM
#ProstateCancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology jnccn.org/view/journal... #Cancer
Weight loss following #nutritional education session among newly diagnosed breast cancer patients link.springer.com/article/10.1... #breastcancer
Weight loss following nutritional education session among newly diagnosed breast cancer patients - Supportive Care in Cancer
Purpose The optimal timing and incorporation of nutritional consultations throughout the cancer journey remain uncertain. Intervening earlier may benefit weight management, prognosis, and long-term ou...
link.springer.com
November 14, 2025 at 11:36 AM
Weight loss following #nutritional education session among newly diagnosed breast cancer patients link.springer.com/article/10.1... #breastcancer
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced #ProstateCancer: EORTC GUCG-1414 euoncology.europeanurology.com/article/S258... #Cancer
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate ...
EORTC 1414 compared degarelix and a luteinizing hormone–releasing hormone agonist
for long-term androgen deprivation in patients who underwent external beam radiotherapy
for prostate cancer. There was...
euoncology.europeanurology.com
November 14, 2025 at 11:28 AM
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced #ProstateCancer: EORTC GUCG-1414 euoncology.europeanurology.com/article/S258... #Cancer
Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed #ProstateCancer Diagnostic Pathway www.europeanurology.com/article/S030...
Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway
The magnetic resonance imaging–directed RAPID pathway is safe up to 5 yr of follow-up,
with no metastases or cancer deaths. Fewer than one in 13 men developed grade group
≥2 prostate cancer, and only ...
www.europeanurology.com
November 14, 2025 at 11:23 AM
Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed #ProstateCancer Diagnostic Pathway www.europeanurology.com/article/S030...
Nivolumab in Metastatic Clear-cell #Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study www.europeanurology.com/article/S030... #Cancer
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
Immune and angiogenic features can help inform response to nivolumab in patients with
metastatic clear-cell renal cell carcinoma. Soluble factors are easily accessible
candidate biomarkers for the act...
www.europeanurology.com
November 14, 2025 at 11:19 AM
Nivolumab in Metastatic Clear-cell #Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study www.europeanurology.com/article/S030... #Cancer
Quality assurance in multi-modality oesophago-gastric cancer clinical trials: past, present and future perspectives www.clinicaloncologyonline.net/article/S093... @velindrecc.bsky.social #Cancer
Quality assurance in multi-modality oesophago-gastric cancer clinical trials: past, present and future perspectives
Clinical trials must ensure the quality of both standard and interventional treatments
to rigorously evaluate potential benefits, avoid adverse outcomes, and maintain integrity
of results. Quality ass...
www.clinicaloncologyonline.net
November 14, 2025 at 11:08 AM
Quality assurance in multi-modality oesophago-gastric cancer clinical trials: past, present and future perspectives www.clinicaloncologyonline.net/article/S093... @velindrecc.bsky.social #Cancer
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart jitc.bmj.com/content/13/1... #Cancer
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart
Background Cancer immunotherapy (CIT) often triggers immune-related adverse events (irAEs). Analysis of irAEs in large checkpoint inhibitor (CPI) trials has enhanced their management and demonstrated ...
jitc.bmj.com
November 14, 2025 at 10:29 AM
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart jitc.bmj.com/content/13/1... #Cancer
Artificial intelligence for early #palliative referral in adult oncology: opportunities, challenges and future directions spcare.bmj.com/content/earl...
Artificial intelligence for early palliative referral in adult oncology: opportunities, challenges and future directions
Background In oncology, early palliative care enhances quality of life and may increase survival; yet, because of resource limitations and overestimation of prognosis, referrals frequently happen late...
spcare.bmj.com
November 14, 2025 at 10:23 AM
Artificial intelligence for early #palliative referral in adult oncology: opportunities, challenges and future directions spcare.bmj.com/content/earl...
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent #ProstateCancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study ascopubs.org/doi/10.1200/... #Cancer
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
PURPOSEProgression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT)
for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed
to assess whether the a...
ascopubs.org
November 14, 2025 at 10:12 AM
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent #ProstateCancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study ascopubs.org/doi/10.1200/... #Cancer
This weeks Immunobuddies episode is out now, get listening!! 🎙️Episode 168: New #Immunotherapies for Community Teams and Non Oncologists Part 2 with Macmillan GP Lead for Wales Dr Elise Lang open.spotify.com/episode/5B8n... @rickyfrazer1.bsky.social @velindrecc.bsky.social #Cancer
Episode 168: New Immunotherapies for Community Teams and Non Oncologists Part 2 with Macmillan GP Lead for Wales Dr Elise Lang
open.spotify.com
November 14, 2025 at 10:02 AM
This weeks Immunobuddies episode is out now, get listening!! 🎙️Episode 168: New #Immunotherapies for Community Teams and Non Oncologists Part 2 with Macmillan GP Lead for Wales Dr Elise Lang open.spotify.com/episode/5B8n... @rickyfrazer1.bsky.social @velindrecc.bsky.social #Cancer
Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery − a secondary analysis of the CYBER-SPACE randomized phase 2 trial www.thegreenjournal.com/article/S016...
Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery − a secondary analysis of the CYBER-SPACE randomized phase 2 trial
The incidence of brain metastases (BM) is rising, driven by several factors: Enhanced
imaging techniques, especially in magnetic resonance imaging (MRI), and their broader
availability have significan...
www.thegreenjournal.com
November 13, 2025 at 1:09 PM
Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery − a secondary analysis of the CYBER-SPACE randomized phase 2 trial www.thegreenjournal.com/article/S016...
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907) www.ejcancer.com/article/S095...
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907)
Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma with a
high metastatic potential. We conducted a phase II clinical study of atezolizumab
in ASPS patients to evaluate its eff...
www.ejcancer.com
November 13, 2025 at 1:00 PM
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907) www.ejcancer.com/article/S095...
If you're not listening to Immunobuddies, is it really Friday?! Episode 167: New Immunotherapies for Community Teams and Non Oncologists Part 1 with Macmillan GP Lead for Wales Dr Elise Lang. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/0ck3...
Episode 167: New Immunotherapies for Community Teams and Non Oncologists Part 1 with Macmillan GP Lead for Wales Dr Elise Lang
open.spotify.com
November 7, 2025 at 11:04 AM
If you're not listening to Immunobuddies, is it really Friday?! Episode 167: New Immunotherapies for Community Teams and Non Oncologists Part 1 with Macmillan GP Lead for Wales Dr Elise Lang. @velindrecc.bsky.social @rickyfrazer1.bsky.social open.spotify.com/episode/0ck3...
Technology Appraisal Guideline: [TA1108] Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell #LungCancer www.nice.org.uk/guidance/ta1...
Overview | Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | Guidance | NICE
www.nice.org.uk
November 7, 2025 at 10:34 AM
Technology Appraisal Guideline: [TA1108] Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell #LungCancer www.nice.org.uk/guidance/ta1...
Factors associated with end-of-life quality in terminally ill #Cancer patients’ last six months of life: a longitudinal study. link.springer.com/article/10.1...
Factors associated with end-of-life quality in terminally ill cancer patients’ last six months of life: a longitudinal study - Supportive Care in Cancer
Context/Purpose Promoting high-quality end-of-life (EOL) care is crucial for cancer patients. We investigated underexplored predictors associated with EOL quality and its domains during the last six m...
link.springer.com
November 7, 2025 at 10:29 AM
Factors associated with end-of-life quality in terminally ill #Cancer patients’ last six months of life: a longitudinal study. link.springer.com/article/10.1...
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in #BreastCancer. www.nejm.org/doi/full/10....
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer | NEJM
The role of postmastectomy chest-wall irradiation in patients with breast cancer classified
as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node
negative) with addit...
www.nejm.org
November 7, 2025 at 10:23 AM
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in #BreastCancer. www.nejm.org/doi/full/10....
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis. jamanetwork.com/journals/jam...
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide
This cohort study investigates the association between older age of an unrelated donor and overall survival in patient receiving posttransplant cyclophosphamide vs conventional calcineurin inhibitor f...
jamanetwork.com
November 7, 2025 at 10:17 AM
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis. jamanetwork.com/journals/jam...
Chemotherapy-associated neutropenia with same-day versus next-day pegfilgrastim in outpatient chemotherapy: solid tumour cohort study. spcare.bmj.com/content/earl...
Chemotherapy-associated neutropenia with same-day versus next-day pegfilgrastim in outpatient chemotherapy: solid tumour cohort study
Objectives To compare the incidence of febrile neutropenia (FN) and chemotherapy delays (CD) due to neutropenia in chemotherapy cycles in which pegfilgrastim (PGF) was administered on the same day (D0...
spcare.bmj.com
November 7, 2025 at 10:12 AM
Chemotherapy-associated neutropenia with same-day versus next-day pegfilgrastim in outpatient chemotherapy: solid tumour cohort study. spcare.bmj.com/content/earl...
Provider billing margin and #Cancer treatment selection: population based cohort study. www.bmj.com/content/391/...
Provider billing margin and cancer treatment selection: population based cohort study
Objective To estimate the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists.
Design Retrospective population based cohort study
Setting...
www.bmj.com
November 7, 2025 at 10:06 AM
Provider billing margin and #Cancer treatment selection: population based cohort study. www.bmj.com/content/391/...
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. ascopubs.org/doi/10.1200/...
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation
PURPOSEZelenectide pevedotin (BT8009) is a Bicycle Drug Conjugate comprising a highly selective
Nectin-4–targeting Bicycle peptide, linked to monomethyl auristatin E. We report monotherapy
dose-escala...
ascopubs.org
November 7, 2025 at 10:02 AM
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. ascopubs.org/doi/10.1200/...